Tag: ticagrelor
ESC 2019: Prasugrel bests ticagrelor for the management of acute coronary syndromes
Stefanie Schüpke (Deutsches Herzzentrum München, and Technische Universität München, Munich, Ger...
PhaseBio receives FDA breakthrough therapy designation for PB2452 for the reversal of the antiplatelet activity of ticagrelor
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) has announced that the US FDA has granted breakthrough...
Ticagrelor significantly reduces the risk of MACE in myocardial infraction patients with multivessel disease
A new subanalysis of the phase III PEGASUS-TIMI 54 trial indicates that ticagrelor (Brilique, As...
Orodispersible tablets of ticagrelor now available in the UK
AstraZeneca has announced the UK availability of ticagrelor (Brilique) 90mg orodispersible tablets. ...
NICE recommends dual antiplatelet therapy with ticagrelor and aspirin
The National Institute of Health and Care Excellence (NICE) has published a final appraisal determin...
ESC 2016: First head-to-head comparisons of prasugrel and ticagrelor shows no significant differences
The initial results of the first randomised controlled trial—PRAGUE 18—to directly compare prasu...
